AstraZeneca Wins Ruling Upholding Key Patent for Farxiga (1)

Oct. 15, 2021, 7:44 PM

AstraZeneca Plc won a federal court ruling upholding a key patent for its diabetes drug Farxiga, staving off threats from cheaper versions.

A trial without a jury in May centered on the validity of a patent that covers Farxiga’s active ingredient, dapagliflozin, its combination with a carrier and methods of treatment. Zydus Cadila conceded infringement before the trial, a common tactic that allowed it to focus on arguments that the patent, which expires in October 2025, wasn’t valid.

U.S. District Judge Richard Andrews in Wilmington, Delaware, rejected Zydus’s arguments that the patent shouldn’t have been issued because it covers an ...

To read the full article log in.

Learn more about a Bloomberg Law subscription